NCT00726505View on ClinicalTrials.gov

Renal Mechanism of Action/Splay vs. TmG

PHASE1TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Diabetes, NOS

Interventions

DRUG

Dapagliflozin

Tablets, Oral, Once Daily, up to 29 days:

Trial Locations (1)

78229

University Of Texas Health Center At San Antonio, San Antonio

Sponsors

Lead Sponsor

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY